Plan Ii Thesis Symposium

Plan Ii Thesis Symposium-71
More recently, Alessio’s Lab has illuminated important structural and mechanistic insights into the molecular recognition and mode of action of PROTAC degrader molecules.Alessio obtained his Ph D in Chemical Biology (University of Cambridge, 2006) studying weak protein-ligand interactions.Bio Alessio Ciulli holds the Personal Chair of Chemical and Structural Biology at the University of Dundee.

More recently, Alessio’s Lab has illuminated important structural and mechanistic insights into the molecular recognition and mode of action of PROTAC degrader molecules.Alessio obtained his Ph D in Chemical Biology (University of Cambridge, 2006) studying weak protein-ligand interactions.Bio Alessio Ciulli holds the Personal Chair of Chemical and Structural Biology at the University of Dundee.

He has a broad expertise in the analysis of structure and function of biological macromolecules and the study of biomolecular interactions using various computational and bioinformatical methods.

He is a member of the Computational Biology and Drug Design research group. Javier Luque is a Professor from the University of Barcelona (UB) and member of the Institute of Biomedicine (IBUB) and Institute of Theoretical and Computational Chemistry (IQTC).

The program will be complemented by poster presentations, and social events on the second day of the conference. Diego Muñoz-Torrero is Associate Professor of Organic and Medicinal Chemistry at the Faculty of Pharmacy and Food Sciences, University of Barcelona (UB).

He is Head of the Laboratory of Pharmaceutical Chemistry and belongs to the Governing Board of the Institute of Biomedicine (IBUB).

400 publications in the field of medicinal chemistry and pharmacology.

Her scientific interests are focused on the medicinal chemistry and molecular pharmacology of purine-binding membrane proteins (purine receptors, ectonucleotidases) and lipid-activated orphan G protein-coupled receptors.

Barril’s research focuses on the discovery of bioactive molecules exploiting unusual mechanisms of action through a combined use of computational and experimental techniques.

He is a well-known expert in the field of structure-based drug discovery, with more than 70 scientific publications.

He is a member of the Computational Biology and Drug Design research group.

Targeting Novel Allosteric Sites with Confidence: Methods and Applications Prof.

SHOW COMMENTS

Comments Plan Ii Thesis Symposium

The Latest from domug.ru ©